Literature DB >> 15051381

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Diana V Pastrana1, Christopher B Buck, Yuk-Ying S Pang, Cynthia D Thompson, Philip E Castle, Peter C FitzGerald, Susanne Krüger Kjaer, Douglas R Lowy, John T Schiller.   

Abstract

Sensitive high-throughput neutralization assays, based upon pseudoviruses carrying a secreted alkaline phosphatase (SEAP) reporter gene, were developed and validated for human papillomavirus (HPV)16, HPV18, and bovine papillomavirus 1 (BPV1). SEAP pseudoviruses were produced by transient transfection of codon-modified papillomavirus structural genes into an SV40 T antigen expressing line derived from 293 cells, yielding sufficient pseudovirus from one flask for thousands of titrations. In a 96-well plate format, in this initial characterization, the assay was reproducible and appears to be as sensitive as, but more specific than, a standard papillomavirus-like particle (VLP)-based enzyme-linked immunosorbent assay (ELISA). The neutralization assay detected type-specific HPV16 or HPV18 neutralizing antibodies (titers of 160-10240) in sera of the majority of a group of women infected with the corresponding HPV type, but not in virgin women. Sera from HPV16 VLP vaccinees had high anti-HPV16 neutralizing titers (mean: 45000; range: 5120-163840), but no anti-HPV18 neutralizing activity. The SEAP pseudovirus-based neutralization assay should be a practical method for quantifying potentially protective antibody responses in HPV natural history and prophylactic vaccine studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15051381     DOI: 10.1016/j.virol.2003.12.027

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  164 in total

1.  Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques.

Authors:  Karen Nieto; Christiane Stahl-Hennig; Barbara Leuchs; Martin Müller; Lutz Gissmann; Jürgen A Kleinschmidt
Journal:  Hum Gene Ther       Date:  2012-04-18       Impact factor: 5.695

2.  Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection.

Authors:  Subhashini Jagu; Kihyuck Kwak; Robert L Garcea; Richard B S Roden
Journal:  Vaccine       Date:  2010-04-29       Impact factor: 3.641

Review 3.  Correlates of protection induced by vaccination.

Authors:  Stanley A Plotkin
Journal:  Clin Vaccine Immunol       Date:  2010-05-12

4.  Detection of HPV types and neutralizing antibodies in women with genital warts in Tianjin City, China.

Authors:  Xue-ling Wu; Chun-tao Zhang; Xiao-ke Zhu; You-chun Wang
Journal:  Virol Sin       Date:  2010-02-12       Impact factor: 4.327

Review 5.  Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins.

Authors:  Xiao Zhang; Lu Xin; Shaowei Li; Mujin Fang; Jun Zhang; Ningshao Xia; Qinjian Zhao
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women.

Authors:  Pascal Azar; José Enrique Mejía; Claire Cenac; Arnoo Shaiykova; Ali Youness; Sophie Laffont; Asma Essat; Jacques Izopet; Caroline Passaes; Michaela Müller-Trutwin; Pierre Delobel; Laurence Meyer; Jean-Charles Guéry
Journal:  JCI Insight       Date:  2020-06-18

Review 7.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

8.  Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2.

Authors:  Ratish Gambhira; Subhashini Jagu; Balasubramanyam Karanam; Patti E Gravitt; Timothy D Culp; Neil D Christensen; Richard B S Roden
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  A paper-based immunoassay to determine HPV vaccination status at the point-of-care.

Authors:  Benjamin D Grant; Chelsey A Smith; Philip E Castle; Michael E Scheurer; Rebecca Richards-Kortum
Journal:  Vaccine       Date:  2016-09-22       Impact factor: 3.641

10.  Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions.

Authors:  Maxime J J Fleury; Antoine Touzé; Silvia de Sanjosé; F Xavier Bosch; Joellen Klaustermeiyer; Pierre Coursaget
Journal:  Clin Vaccine Immunol       Date:  2007-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.